SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors were introduced as a treatment for T2D but by virtue of the associated urinary excretion of glucose (and thus caloric loss), and urinary excretion of sodium, their use is associated with reductions in HbA1c levels, body weight and systolic blood pressure.